September 10th 2025
According to Sundar Jagannath, MBBS, the cure for multiple myeloma was observed in patients who were cancer free for 5 years without maintenance therapy.
September 5th 2025
Quiz: What Newly Approved Drug Treats Bone Metastases in Multiple Myeloma?
February 15th 2018Do you know what dose of carfilzomib is associated with an increased incidence of cardiovascular events in multiple myeloma patients? How about the estimated incidence of new myeloma cases in 2018? Test your knowledge in our latest quiz.
Quiz: Do Bisphosphonates for Multiple Myeloma Improve Survival?
January 20th 2018Is the use of bisphosphonates in patients with multiple myeloma associated with improved progression-free or overall survival? Is hypertension a risk factor for carfilzomib-related cardiopulmonary toxicities? Test your knowledge in our latest quiz.
Early Promise for Experimental Antibody-Drug Conjugate in Multiple Myeloma
December 13th 2017An investigational antibody-drug conjugate that targets a key B-cell maturation antigen, offers “deep and durable” responses to some patients with relapsed/refractory multiple myeloma, suggest preliminary findings from the expansion part of the phase I DREAMM-1 trial.
Adding Daratumumab to SOC Delays Progression in Advanced Multiple Myeloma
December 13th 2017Adding daratumumab to either of two standard-of-care treatment regimens induces rapid, deep, and durable responses and improves progression-free survival in patients with relapsed/refractory multiple myeloma, confirm updated findings from the open-label phase III POLLUX and CASTOR trials.
Anti-BCMA CAR T-Cell Therapy Active in Heavily Pretreated Myeloma
December 11th 2017A single treatment with a second-generation CAR T-cell treatment elicited an overall response rate of 94% in a small study of patients with heavily pretreated multiple myeloma, according to the results of a phase I study presented at the ASH Annual Meeting.
Lenalidomide Maintenance Therapy Outperforms Observation in Newly Diagnosed Multiple Myeloma
December 11th 2017Continuous lenalidomide therapy improves outcomes among patients with newly diagnosed myeloma who are not autologous stem cell transplant candidates, according to findings from a large phase III clinical trial.
Which Drug Is Contraindicated in RVD-Treated Multiple Myeloma Patients?
December 1st 2017Do you know when to switch treatment combinations or stop certain treatments altogether in the management of patients with multiple myeloma? Take part in a series of case scenarios and see if you can pick the correct course of action for each in our latest quiz.
CRP Levels Before Transplant Linked With Survival in Multiple Myeloma
November 29th 2017Elevated pre-transplant C-reactive protein was associated with worse overall survival in patients who underwent autologous stem cell transplantation for multiple myeloma, particularly in those who had transplant more than 12 months after diagnosis.